证券代码：603139 证券简称：康惠制药 公告编号：2025-054 陕西康惠制药股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 4 日 (二)股东大会召开的地点：咸阳市秦都区胭脂路 36 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 104 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 44,758,537 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 44.8123 | | 总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，以现场和网络投票相结合的方式召开，现 场会议由公司董事长王延岭先生主持。本次股东大会的召集、召开和决策程序， 符合《 ...

致：陕西康惠制药股份有限公司 北京市金杜律师事务所上海分所关于 陕西康惠制药股份有限公司 2025 年第二次临时股东大会 之法律意见书 北京市金杜律师事务所上海分所（以下简称本所）接受陕西康惠制药股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以 下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳 门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和 现行有效的《陕西康惠制药股份有限公司章程》（以下简称《公司章程》）有关规 定，指派律师出席并见证公司于 2025 年 9 月 4 日召开的 2025 年第二次临时股东 大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2021 年年度股东大会审议批准的《公司章程》； 2. 公司 2025 年 8 月 20 日刊登于巨潮资讯网、《中国证券报 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-055 陕西康惠制药股份有限公司 第六届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 9 月 4 日召开 2025 年第二次临时股东大会，选举产生了第六届董事会成员。为保证公司董事 会顺利运行，经全体董事同意后，豁免会议通知时间要求，现场决定召开公司第 六届董事会第一次会议。会议应出席董事 9 人，实际参加董事 9 人。本次会议由 全体董事推举的董事李红明先生主持。本次会议符合《公司法》、《公司章程》和 《董事会议事规则》的有关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 经与会董事审议和表决，通过了以下决议： 2、审议通过《关于选举公司第六届董事会专门委员会委员的议案》 本次会议选举第六届董事会各专门委员会委员，任期与第六届董事会一致， 自本次董事会审议通过之日起三年。公司董事会下设战略委员会、审计委员会、 提名委员会及薪酬与考核委员会， ...

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang [1][2] Group 1: Company Operations - Shaanxi Youbang, a subsidiary of the company, is experiencing continuous losses due to product adjustments and production challenges, prompting a decision to halt production in workshops 1, 2, and 3 [1] - The halt in production is expected to mitigate further losses and reduce operational costs, aligning with the company's strategic development direction [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets are projected to account for 16.91% of the company's most recent audited total assets, with its revenue contributing 1.42% to the consolidated revenue [2] - The projected net loss for Shaanxi Youbang in 2024 is estimated at 52.51 million yuan, impacting the company's net profit by 26.78 million yuan, which represents 29.88% of the company's net profit attributable to shareholders [2]

人民财讯9月4日电，康惠制药（603139）9月4日晚间公告，为了减少亏损，维护股东利益，公司控股子 公司陕西友帮生物医药科技有限公司(简称"陕西友帮")已于近日停产，后续将根据市场情况决定是否恢 复生产。此次停产预计将可能对相关主体关于陕西友帮的业绩承诺完成情况造成一定影响。 ...

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang to mitigate losses and protect shareholder interests [1][2] Group 1: Company Operations - Shaanxi Youbang, a subsidiary of Kanghui Pharmaceutical, is experiencing continuous losses and has decided to halt production in workshops 1, 2, and 3 due to unsuccessful product adjustments and production challenges [1] - The halt in production is expected to help the company avoid further losses and reduce operational costs, aligning with the company's strategic development direction [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets accounted for 16.91% of the company's most recent audited total assets, while its revenue represented 1.42% of the consolidated revenue [2] - The net profit for Shaanxi Youbang in 2024 is projected to be -52.51 million, impacting the company's audited net profit attributable to shareholders by -26.78 million, which constitutes 29.88% of the total [2]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.82% on September 4, with ST Xiangxue leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Wanbangde (002082) with a closing price of 9.98, up 3.42% and a trading volume of 487,100 shares, totaling 482 million yuan [1] - Shengtang Pharmaceutical (833266) closed at 11.20, up 2.38% with a trading volume of 39,300 shares, totaling 44.12 million yuan [1] - Significant decliners included: - ST Qingyin (300147) with a closing price of 10.18, down 6.86% and a trading volume of 288,600 shares, totaling 301 million yuan [2] - Weikang Pharmaceutical (300878) closed at 21.42, down 6.83% with a trading volume of 54,300 shares, totaling 118 million yuan [2] Capital Flow - The traditional medicine sector saw a net outflow of 819 million yuan from institutional investors, while retail investors contributed a net inflow of 925 million yuan [2] - The capital flow for specific stocks showed: - Wanbangde (002082) had a net inflow of 30.53 million yuan from institutional investors, while retail investors had a net outflow of 19.38 million yuan [3] - Jianmin Group (600976) experienced a net inflow of 26.19 million yuan from institutional investors, with retail investors seeing a net outflow of 23.73 million yuan [3]

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

Core Viewpoint - The financial performance of Kanghui Pharmaceutical (603139) for the first half of 2025 shows significant declines in revenue and profit, indicating increased short-term debt pressure and a challenging operational environment [1] Financial Performance Summary - Total revenue for the first half of 2025 was 248 million yuan, a decrease of 6.83% year-on-year [1] - Net profit attributable to shareholders was -40.20 million yuan, a decline of 362.01% year-on-year [1] - Gross margin decreased to 26.44%, down 19.17% year-on-year, while net margin fell to -23.17%, a drop of 259.76% [1] - Total expenses (selling, administrative, and financial) reached 111 million yuan, accounting for 44.93% of revenue, an increase of 19.54% year-on-year [1] - Earnings per share were -0.40 yuan, a decrease of 344.44% year-on-year [1] Cash Flow and Debt Analysis - Cash flow from operating activities showed a negative trend, with operating cash flow per share at -0.17 yuan, down 19.36% year-on-year [1] - The liquidity ratio was reported at 0.96, indicating rising short-term debt pressure [1] - The company’s cash and cash equivalents decreased by 34.66% to 113 million yuan [3] Business Model and Market Position - The company relies heavily on marketing-driven strategies, which necessitates a thorough examination of the underlying factors driving this approach [8] - The pharmaceutical industry is characterized by high technology, high investment, and long cycles, with increasing demand due to aging populations and rising chronic disease rates [11] - The company aims to enhance its operational efficiency and adapt to policy changes in the healthcare sector, focusing on key therapeutic areas such as respiratory, dermatology, gynecology, and orthopedics [12] Future Outlook - The company plans to leverage its strengths in research and development, production technology, and market services to improve its market position and operational performance [12] - There is a strategic focus on expanding into retail and grassroots medical markets, as well as exploring opportunities in the Internet and artificial intelligence sectors [12]

Core Viewpoint - The company is holding a shareholders' meeting to discuss various governance changes, including the abolition of the supervisory board and amendments to the company's articles of association [5][6][7]. Meeting Procedures - All attendees must register 30 minutes prior to the meeting and present valid identification to participate in voting and discussions [1][2]. - Shareholders have the right to speak, inquire, and vote during the meeting, but must register to speak 15 minutes before the meeting starts [2][3]. - The meeting will utilize both on-site and online voting methods, with each share entitled to one vote [2][3]. Agenda Items - Proposal to abolish the supervisory board and amend the articles of association, transferring the supervisory functions to the audit committee of the board [5]. - Amendments to the rules governing shareholder meetings to enhance corporate governance [6]. - Amendments to the rules governing board meetings to improve operational standards [7]. - Proposal to revise the independent director system to align with regulatory requirements [8]. - Proposal to amend the external investment management system to ensure compliance with legal standards [9]. - Proposal to revise the external guarantee management system to enhance risk management [9]. - Proposal to amend the related party transaction management system to ensure transparency [10]. - Proposal to revise the accountant selection system to ensure proper financial oversight [11]. - Election of the sixth board of directors, including both non-independent and independent directors, due to the expiration of the current board's term [12][13]. Meeting Logistics - The meeting is scheduled for September 4, 2025, at 2:30 PM, with specific time slots for online voting [3][4]. - The venue for the meeting is located at the company's headquarters in Xi'an [4]. Legal Oversight - The meeting will be witnessed by a law firm to ensure compliance with legal standards and provide a legal opinion on the proceedings [3].